Panniculectomy With Umbilical Transposition in the Era of Glucagon-Like Peptide-1 Receptor Agonists: The Impact of Weight Loss Modality on Postoperative Outcomes.

@article{fallah2026panniculectomy,
  title = {{Panniculectomy With Umbilical Transposition in the Era of Glucagon-Like Peptide-1 Receptor Agonists: The Impact of Weight Loss Modality on Postoperative Outcomes.}},
  author = {Kasra N Fallah and Parhom N Towfighi and Louis Massoud and Angad S Sidhu and Dillon C Mobasser and Aniffa S Kouton and Ryan D Harmelink and Nikhi P Singh and George S Corpuz and Ravinder Bamba and Rachel M Danforth and Richard J VonDerHaar and Mary E Lester and Aladdin H Hassanein and Ivan Hadad},
  journal = {Aesthetic surgery journal. Open forum},
  year = {2026},
  month = oct,
  doi = {10.1093/asjof/ojag206},
  url = {https://europepmc.org/article/MED/42997336},
  note = {CC BY},
}

TY  - JOUR
TI  - Panniculectomy With Umbilical Transposition in the Era of Glucagon-Like Peptide-1 Receptor Agonists: The Impact of Weight Loss Modality on Postoperative Outcomes.
AU  - Kasra N Fallah
AU  - Parhom N Towfighi
AU  - Louis Massoud
AU  - Angad S Sidhu
AU  - Dillon C Mobasser
AU  - Aniffa S Kouton
AU  - Ryan D Harmelink
AU  - Nikhi P Singh
AU  - George S Corpuz
AU  - Ravinder Bamba
AU  - Rachel M Danforth
AU  - Richard J VonDerHaar
AU  - Mary E Lester
AU  - Aladdin H Hassanein
AU  - Ivan Hadad
PY  - 2026
DA  - 2026/10/15
JO  - Aesthetic surgery journal. Open forum
DO  - 10.1093/asjof/ojag206
UR  - https://europepmc.org/article/MED/42997336
AB  - Panniculectomy is performed to address excess infraumbilical skin and soft tissue following weight loss. Weight loss can be achieved through lifestyle modifications, bariatric surgery, and pharmacologic therapies, such as glucagon-like peptide-1 (GLP-1) agonists. The impact of weight loss modality on postoperative outcomes remains unclear. The aim of this study was to evaluate whether the method of weight loss influences postoperative outcomes following panniculectomy. A single-center retrospective review was conducted of patients who underwent panniculectomy between 2021 and 2025. Patients were grouped into 4 cohorts: lifestyle modifications alone, bariatric surgery, GLP-1 agonist therapy, or combined bariatric surgery and GLP-1 agonist therapy. Patients receiving abdominoplasty with extensive undermining and rectus plication were excluded. Variables of interest included patient demographics, weight loss history, comorbidities, wound-healing complications, surgical-site infection, hematoma/seroma, and hospital utilization. Multivariate logistic regression was performed to analyze postoperative complications and healthcare utilization, with statistical significance set at P < .05. A total of 281 patients met inclusion criteria (lifestyle modifications: n = 53 [18.9%]; bariatric surgery: n = 184 [65.5%]; GLP-1 agonist therapy: n = 20 (7.1%); and combined bariatric surgery and GLP-1 agonist therapy: n = 24 [8.5%]). Multivariate analysis showed no statistically significant differences in postoperative outcomes, including wound complications, surgical-site infections, seroma/hematoma, or hospital utilization. Postoperative outcomes following panniculectomy may be similar regardless of weight loss method. Preoperative GLP-1 agonist therapy, alone or combined with bariatric surgery, was not associated with increased postoperative complications or healthcare utilization. Our results can help guide risk stratification and decision making for individuals pursuing panniculectomy after weight loss.
SN  - 2631-4797
ER  -